摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-chloro-2-sulfanylbenzoate | 1134541-04-0

中文名称
——
中文别名
——
英文名称
methyl 3-chloro-2-sulfanylbenzoate
英文别名
——
methyl 3-chloro-2-sulfanylbenzoate化学式
CAS
1134541-04-0
化学式
C8H7ClO2S
mdl
——
分子量
202.661
InChiKey
HVZPRWFTASHFOC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    27.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    methyl 3-chloro-2-sulfanylbenzoate 在 lithium aluminium tetrahydride 、 碳酸氢钠potassium carbonate对甲苯磺酸三乙胺 作用下, 以 四氢呋喃二氯甲烷N,N-二甲基甲酰胺甲苯乙腈 为溶剂, 反应 24.58h, 生成 (9H-fluoren-9-yl)methyl 2-((4-bromo-2-(1,3-dioxolan-2-yl)phenyl)thio)-3-chlorobenzylcarbamate
    参考文献:
    名称:
    [EN] PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII
    [FR] MACROCYCLES PEPTIDIQUES CONTRE ACINETOBACTER BAUMANNII
    摘要:
    本发明提供了式(I)的化合物,其中X1至X8和R1至R8如本文所述,以及其药学上可接受的盐。此外,本发明涉及制备式(I)的化合物,包括它们的药物组合物以及它们作为治疗由鲍曼不动杆菌引起的疾病和感染的药物的用途。
    公开号:
    WO2017072062A1
  • 作为产物:
    描述:
    3-氯-2-氟苯甲醛 在 sodium sulfide 、 sodium chlorite硫酸 作用下, 以 N,N-二甲基甲酰胺丙酮 为溶剂, 反应 18.58h, 生成 methyl 3-chloro-2-sulfanylbenzoate
    参考文献:
    名称:
    [EN] PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII
    [FR] MACROCYCLES PEPTIDIQUES CONTRE ACINETOBACTER BAUMANNII
    摘要:
    本发明提供了式(I)的化合物,其中X1至X8和R1至R8如本文所述,以及其药学上可接受的盐。此外,本发明涉及制备式(I)的化合物,包括它们的药物组合物以及它们作为治疗由鲍曼不动杆菌引起的疾病和感染的药物的用途。
    公开号:
    WO2017072062A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL ANDROGENS<br/>[FR] ANDROGENES
    申请人:AKZO NOBEL NV
    公开号:WO2005102998A1
    公开(公告)日:2005-11-03
    The compounds of the subject invention have a structure according to formula I: wherein X is S or SO2; R1 is (1C-6C)alkyl, (3C-6C)alkenyl, or (3C-6C)alkynyl, each optionally subst ituted with (3C-6C)cycloalkyl, OH, OC(O)(1C-4C)alkyl, (1C- 4C)alkoxy, halogen, cyano, formyl, C(O)(1C-4C)alkyl, CO2H, CO2(1C- 4C)alkyl, C(O)NR5R6, S(O)(1C-4C)alkyl or S(O)2(1C-4C)alkyl; R2 is hydrogen, (1C-4C)alkyl or C(O)(1C-4C)alkyl; R3 is a phenyl group optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, (1C-4C)fluoroalkoxy, halogen, cyano or nitro; or R3 is a 5- or 6-membered aromatic heterocyclic ring structure optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, halogen or cyano; R4 is a phenyl group or an aromatic 6-membered heterocycle, substituted at the ortho position with 1-hydroxy(1C-4C)alkyl, (1C-4C)alkoxy, C(O)(1C- 4C)alkyl, CO2(1C-4C)alkyl, C(O)NH2, cyano, nitro, or CH=NOR7, and optionally further substituted with (1C-2C)alkyl, (1C-2C)fluoroalkyl or halogen; R5 is 2-pyridyl optionally substituted with (1C-2C)alkyl, (1C- 2C)fluoroalkyl or halogen; or R5 and R6 are independently hydrogen or (1C-4C)alkyl; R7 is hydrogen or C(O)(1C-4C)alkyl; R8 , R9 , R10 are independently hydrogen, (1C-2C)alkyl, fluoro or chloro; or a salt or hydrate form thereof.
    本发明的化合物具有如下结构:其中X为S或SO2;R1为(1C-6C)烷基,(3C-6C)烯基或(3C-6C)炔基,每个基可选择地被(3C-6C)环烷基,羟基,OC(O)(1C-4C)烷基,(1C-4C)氧烷基,卤素,氰基,甲酰基,C(O)(1C-4C)烷基,CO2H,CO2(1C-4C)烷基,C(O)NR5R6,S(O)(1C-4C)烷基或S(O)2(1C-4C)烷基取代;R2为氢,(1C-4C)烷基或C(O)(1C-4C)烷基;R3为苯基,可选择地被(1C-4C)烷基,(1C-4C)氟烷基,(1C-4C)氧烷基,(1C-4C)氟氧烷基,卤素,氰基或硝基取代;或R3为5-或6-成员芳香杂环环结构,可选择地被(1C-4C)烷基,(1C-4C)氟烷基,(1C-4C)氧烷基,卤素或氰基取代;R4为苯基或芳香6-成员杂环,取代基在邻位为1-羟基(1C-4C)烷基,(1C-4C)氧烷基,C(O)(1C-4C)烷基,CO2(1C-4C)烷基,C(O)NH2,氰基,硝基或CH=NOR7,并可选择地进一步被(1C-2C)烷基,(1C-2C)氟烷基或卤素取代;R5为2-吡啶基,可选择地被(1C-2C)烷基,(1C-2C)氟烷基或卤素取代;或R5和R6分别为氢或(1C-4C)烷基;R7为氢或C(O)(1C-4C)烷基;R8,R9,R10分别为氢,(1C-2C)烷基,氟或氯;或其盐或水合物形式。
  • Novel Androgens
    申请人:Van Der Louw Jaap
    公开号:US20070225352A1
    公开(公告)日:2007-09-27
    The compounds of the subject invention have a structure according to formula I: wherein each of the substituents is given the definition as set forth in the specification and claims, or a salt or hydrate form thereof.
    该主题发明的化合物具有以下公式I的结构:其中每个取代基的定义如规范和要求中所述,或其盐或水合物形式。
  • HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE
    申请人:Itai Akiko
    公开号:US20100234363A1
    公开(公告)日:2010-09-16
    Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein X is O or S, a broken line and a wavy line represent the presence or the absence of a bond, (i) when a broken line represents the presence of a bond, a wavy line represents the absence of a bond, R 2 and R 3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, (ii) when a broken line represents the absence of a bond, a wavy line represents the presence of a bond, R 1 and R 4 are each independently hydrogen, halogen or the like, R 2 and R 3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, and R 5 and R 6 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like.
    本发明涉及一种化合物,可用作11β-羟基类固醇脱氢酶1型抑制剂。化合物的表示式如下:其药学上可接受的盐或其溶剂化物,其中X为O或S,一条断线和一条波浪线分别表示键的存在或不存在,(i) 当断线表示键的存在时,波浪线表示键的不存在,R2和R3各自独立地表示氢、卤素、氰基、羟基、羧基、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物,(ii) 当断线表示键的不存在时,波浪线表示键的存在,R1和R4各自独立地表示氢、卤素或类似物,R2和R3各自独立地表示氢、卤素、氰基、羟基、羧基、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物,而R5和R6各自独立地表示氢、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物。
  • NOVEL ANDROGENS
    申请人:Van Der Louw Jaap
    公开号:US20110009428A1
    公开(公告)日:2011-01-13
    The compounds of the subject invention have a structure according to formula I: wherein X is S or SO 2 ; R 1 is (1C-6C)alkyl, (3C-6C)alkenyl, or (3C-6C)alkynyl, each optionally substituted with (3C-6C)cycloalkyl, OH, OC(O)(1C-4C)alkyl, (1C-4C)alkoxy, halogen, cyano, formyl, C(O)(1C-4C)alkyl, CO 2 H, CO 2 (1C-4C)alkyl, C(O)NR 5 R 6 , S(O)(1C-4C)alkyl or S(O) 2 (1C-4C)alkyl; R 2 is hydrogen, (1C-4C)alkyl or C(O)(1C-4C)alkyl; R 3 is a phenyl group optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, (1C-4C)fluoroalkoxy, halogen, cyano or nitro; or R 3 is a 5- or 6-membered aromatic heterocyclic ring structure optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, halogen or cyano; R 4 is a phenyl group or an aromatic 6-membered heterocycle, substituted at the ortho position with 1-hydroxy(1C-4C)alkyl, (1C-4C)alkoxy, C(O)(1C-4C)alkyl, CO 2 (1C-4C)alkyl, C(O)NH 2 , cyano, nitro, or CH═NOR 7 , and optionally further substituted with (1C-2C)alkyl, (1C-2C)fluoroalkyl or halogen; or R 4 is 2-pyridyl optionally substituted with (1C-2C)alkyl, (1C-2C)fluoroalkyl or halogen; R 5 and R 6 are independently hydrogen or (1C-4C)alkyl; R 7 is hydrogen or C(O)(1C-4C)alkyl; R 8 , R 9 , R 10 are independently hydrogen, (1C-2C)alkyl, fluoro or chloro; or a salt or hydrate form thereof.
    该发明的化合物具有以下式子的结构:其中X为S或SO2;R1为(1C-6C)烷基,(3C-6C)烯基或(3C-6C)炔基,每个基团可选择性地用(3C-6C)环烷基、OH、OC(O)(1C-4C)烷基、(1C-4C)烷氧基、卤素、氰基、甲酰基、C(O)(1C-4C)烷基、CO2H、CO2(1C-4C)烷基、C(O)NR5R6、S(O)(1C-4C)烷基或S(O)2(1C-4C)烷基取代;R2为氢、(1C-4C)烷基或C(O)(1C-4C)烷基;R3为苯基,可选择性地用(1C-4C)烷基、(1C-4C)氟代烷基、(1C-4C)烷氧基、(1C-4C)氟代烷氧基、卤素、氰基或硝基取代;或者R3为5-或6-成员的芳香杂环结构,可选择性地用(1C-4C)烷基、(1C-4C)氟代烷基、(1C-4C)烷氧基、卤素或氰基取代;R4为苯基或芳香6-成员杂环,在邻位用1-羟基(1C-4C)烷基、(1C-4C)烷氧基、C(O)(1C-4C)烷基、CO2(1C-4C)烷基、C(O)NH2、氰基、硝基或CH═NOR7取代,可选择性地进一步用(1C-2C)烷基、(1C-2C)氟代烷基或卤素取代;或者R4为2-吡啶基,可选择性地用(1C-2C)烷基、(1C-2C)氟代烷基或卤素取代;R5和R6独立地为氢或(1C-4C)烷基;R7为氢或C(O)(1C-4C)烷基;R8、R9和R10独立地为氢、(1C-2C)烷基、氟或氯;或其盐或水合物形式。
  • Peptide macrocycles against acinetobacter baumannii
    申请人:Hoffmann-La Roche Inc.
    公开号:US10030047B2
    公开(公告)日:2018-07-24
    The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.
    本发明提供了式 (I) 的化合物 其中 X1 至 X8 和 R1 至 R8 如本文所述,以及其药学上可接受的盐。此外,本发明还涉及式(I)化合物的制造、包含它们的药物组合物以及它们作为治疗鲍曼不动杆菌引起的疾病和感染的药物的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐